Heartseed
Business Services · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
302 Art Complex Center 12-9 Daikyocho, D...Phone Number
+81 363801068Website
www.heartseed.jpRevenue
$15.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Heartseed
Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production. It is headquartered in Tokyo, Japan.Explore more
Heartseed Org Chart
KY
Chief Operating Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Heartseed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Heartseed has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Heartseed has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Heartseed recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Heartseed launches new products
Congratulate Masked Content for being promoted to Masked Content at Heartseed
Heartseed, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Heartseed had a recent Job posting/layoffs
Check out if Heartseed is spiking on competitors!
Recommended Actions
Find VP level buyers at Heartseed
Find 3 more new buyers
Company Profile Activity
Activity Insights
Heartseed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Heartseed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Heartseed.
Heartseed financials insights
Gather financial insights about Heartseed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$7.3M
2019
Series B
$26M
2021
Series C
$37M
2023
Series D
$14.3M
Heartseed Tech Stack
A closer look at the technologies used by Heartseed
Most Recent Scoops
Funding
Funding
Promotion
Executive Move
Promotion
Funding
Funding
Heartseed News & Media
Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
TOKYO & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Heartseed--Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed's proprietary cardiomyocytes differentiation and purification methods. As a result, Heartseed has successfully producHeartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
TOKYO--(BUSINESS WIRE)-- #HS001--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology (JCC) on September 9, 2023. Dr. Yuki Ichihara, DHeartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy
TOKYO--(BUSINESS WIRE)-- #License--Heartseed Inc. (CEO: Keiichi Fukuda) today announced that it has entered into a worldwide non-exclusive patent license agreement (“Agreement”) with an undisclosed biotech company (“Licensee”) for its Metabolic Selection technology, a proprietary platform used to selectively remove undifferentiated induced pluripotent stem cells (iPSCs). This technology addresses the need to eliminate potentially tumor-causing undifferentiated iPSCs as the clinical use of iPSC-bHeartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
TOKYO--(BUSINESS WIRE)-- #biotech--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx. $74 million) since it was founded in 2015. New investors are Japan Co-Invest IV Limited Partnership (GP: Sumitomo Mitsui Trust Investment), Arcus South East Asia, Atsushi Sakano (Partner of Aspex Management),
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Heartseed
Sign Up For FreeTo access detailed company insights
Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purifi... Read More
